The Latest Cardiac and Vascular News
Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019. “We are pleased with our second quarter results, as stronger execution led to a sequential improvement in revenue,” commented John Onopchenko, […]
— Corindus Stockholders to Receive $4.28 Per Share — — All-Cash Transaction Valued at Approximately $1.1 Billion — WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. […]
NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the “Reducer”) for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million Regained Compliance […]
Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of August 12th; Topline Data Accelerated to 2nd Quarter 2020 Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491 on Track for Fourth Quarter 2019 Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. […]
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million private placement. In this private placement, Stereotaxis is selling […]
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently with this release, Stereotaxis announced a $25 million private […]
Corindus announced today a definitive agreement to be acquired by Siemens Healthineers for approximately $1.1 billion, or $4.28 per share, in an all-cash transaction Second quarter revenue of $4.6 million reflects increasing adoption and utilization in U.S. and abroad WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer […]
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ: ABMD) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and […]
SAN CARLOS, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) — BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the closing of its previously announced public offering of 1,666,667 units at a price to the public of $6.00 per unit. Each unit issued […]
